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ABSTRACT 
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   This study examined the mechanisms underlying the interactions between the natural 
polyphenol Resveratrol and HDAC inhibitors in both U937 myelomonocytic leukemia cell line 
and blood samples from AML patients and normal cord blood. Simultaneous exposure to 
Resveratrol and HDAC inhibitors (Vorinostat-SAHA or Panobinostat-LBH589) resulted in 
potentiating the lethality caused by any single agent of the combination, this interaction found to 
be synergistic at multiple concentrations. Exposing U937 cells to minimal toxic doses of 
Resveratrol and HDACIs results in release of mitochondrial pro-apoptotic proteins AIF and 
cytochrome c, pro-apoptotic caspase activation especially caspase-8, and induction of DNA 
damage. These events were associated with increase deacetylation of NF-κB and reactive oxygen 
species generation, as well as G0-G1 cell cycle arrest. Genetic knockdown of SIRT1 (a 
deacetylator of NF-κB that is upregulated by Resveratrol) resulted in significant increase in NF-
κB acetylation and activity. However, SIRT1 knock down failed to protect U937 cells against 
combination-induced cell death, implying the possibility of the involvement of other mechanisms 
in inducing cell death rather than NF-κB deactivation only. Co-incubation of the antioxidant  
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MnTBAP significantly reduced Resveratrol/HDACIs induced cell death, and resulted in a 
marked decrease in caspase-8, caspase-3, and PARP activation. Finally, the combined treatment 
of Resveratrol/HDACIs induce cell cycle changes possibly through Resveratrol action of 
blocking cell cycle in S phase exposing more cells to HDACIs lethality. Collectively, these 
finding indicate that the combined regimen of Resveratrol and HDAC inhibitors promote 
lethality in U937 cells and primary AML cells by a variety of mechanisms. The approved use of 
both agents in clinical setting make future clinical studies for development of this drug regimen a 
potential option in the battle with leukemia. 
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